binx health , a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Todd Bennett as Chief Commercial Officer (CCO). Bennett is an accomplished industry veteran, having held multiple executive leadership roles at several high-growth companies including Luminex, Immucor, Roche and Abbott.
“We are thrilled to welcome someone of Todd’s vast accomplishment, operational, and commercial skill to binx,” said Jeff Luber, binx health CEO. “As we seek to address the increasing need for near-patient testing solutions, I look forward to the vision, creativity, and passion Todd will bring to binx on our commercial journey.”
Bennett’s excellence in leadership and commercial and operational management has consistently delivered breakthrough results. He brings proven experience at building empowered, high performing teams that exceed financial objectives and deliver on commitments as well as multiple successful transactions.
“We are clearly at a point where headwind is switching to tailwind when it comes to personal testing and care. I am honored to have the exciting opportunity to join binx health at an inflection point in its commercial development,” said Bennett. “I am looking forward to joining the very talented, dedicated team of binx employees worldwide who are working to accelerate the growth of the company’s pipeline of highly differentiated products and solutions.”
binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop. The Company works with large corporate partners and institutions who have access to large patient populations and have a significant interest in delivering or facilitating better healthcare to provide access to and enable more streamlined delivery of diagnostic testing and care. Its omnichannel platform includes the point-of-care* io *platform, which puts central-lab quality testing solutions in the hands of clinicians everywhere, and the Company's suite of physician-mediated and medical guideline-driven, at-home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital integration capability to those unable or unwilling to visit a clinic location.
binx's io platform is the first ever FDA-cleared, CLIA-waived point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in about thirty minutes. Its platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance and for the first time enabling single-visit test and treatment. For more information, visit www.binx.com.
Tony Berry LaVoieHealthScience email@example.com (774) 317-0422